Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
13(65%)
Results Posted
50%(2 trials)

Phase Distribution

Ph not_applicable
8
40%
Ph phase_2
4
20%
Ph phase_3
2
10%
Ph phase_1
3
15%

Phase Distribution

3

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution17 total trials
Phase 1Safety & dosage
3(17.6%)
Phase 2Efficacy & side effects
4(23.5%)
Phase 3Large-scale testing
2(11.8%)
N/ANon-phased studies
8(47.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

13

trials recruiting

Total Trials

20

all time

Status Distribution
Active(13)
Completed(4)
Terminated(2)
Other(1)

Detailed Status

Active, not recruiting7
Recruiting6
Completed4
Withdrawn2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
20
Active
13
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (17.6%)
Phase 24 (23.5%)
Phase 32 (11.8%)
N/A8 (47.1%)

Trials by Status

completed420%
unknown15%
withdrawn210%
active_not_recruiting735%
recruiting630%

Recent Activity

Clinical Trials (20)

Showing 20 of 20 trials
NCT05304585Phase 3

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Recruiting
NCT04513717Phase 3

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Active Not Recruiting
NCT02339571Phase 2

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Active Not Recruiting
NCT02496663Phase 1

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

Active Not Recruiting
NCT02775851Phase 2

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

Active Not Recruiting
NCT03831932Phase 1

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Active Not Recruiting
NCT02298959Phase 1

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

Active Not Recruiting
NCT04373720Not Applicable

MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas

Recruiting
NCT05957679Not Applicable

MRE Evaluation for Spinal Cord Tumor Surgery: Stiffness and Adhesion Assessment

Recruiting
NCT06955208Not Applicable

3D MRE-Based Evaluation of Meningioma Mechanical Properties and Histological Features

Recruiting
NCT04550481Phase 2

Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

Active Not Recruiting
NCT04365855Not Applicable

The Olmsted NAFLD Epidemiology Study (TONES)

Recruiting
NCT05990244Not Applicable

Magnetic Resonance Elastography in Glioma: Exploring Tumor Stiffness and Adhesion

Recruiting
NCT05840770Phase 2

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

Withdrawn
NCT05516485Not Applicable

Measuring Brain Tumor Consistency Using Magnetic Resonance Elastography

Withdrawn
NCT04022746Not Applicable

An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer

Completed
NCT01447667Not Applicable

Magnetic Resonance Elastography (MRE) as a Predictor of HCC Recurrence After Radiofrequency Ablation (RFA)

Completed
NCT03401814

Imaging Response to Immunotherapy and Radiation Therapy in Patients With Liver Metastases

Completed
NCT04361578

Magnetic Resonance Elastography in Patients With Acute Closed Traumatic Brain Injury

Unknown
NCT03260660

Comparison of MR Elastography Methods Without and With Compressed Sensing

Completed

All 20 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
20